文献速递妇科

循环游离肿瘤人乳头瘤病毒DNA是宫颈癌中有前景的生物标志物

Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
PubMed 文献 · Gynecol Oncol · 2022-07-30

研究纳入18例局部晚期宫颈癌、15例早期宫颈癌和21例癌前病变患者,采用微滴数字PCR检测治疗前、中、后血浆HPV16、18和45型游离DNA及总游离DNA负荷。局部晚期宫颈癌治疗前检出率为94.4%,早期为26.7%,癌前病变均为阴性;治疗结束时持续检出ctHPV DNA与更差的无进展生存期显著相关(P=0.007)。

要点

  • 局部晚期宫颈癌治疗前ctHPV DNA检出率为94.4%,早期宫颈癌为26.7%,癌前病变均为阴性。
  • 治疗结束时持续检出ctHPV DNA的局部晚期宫颈癌患者无进展生存期显著更差(P=0.007)。
  • 治疗前总ctDNA水平高于中位数的患者无进展生存期更差(P=0.026)。

核心结论

  • ctHPV DNA是局部晚期宫颈癌中有前景的预后生物标志物,应进一步研究以用于临床。

研究设计与样本

  • 研究纳入18例局部晚期宫颈癌、15例早期宫颈癌和21例癌前病变患者,所有病灶均经证实为HPV16、18或45型阳性。
  • 采用微滴数字PCR检测治疗前、治疗中和治疗后血浆中的HPV16、18和45型DNA及总游离DNA负荷,并以cfAlbumin DNA作为总游离DNA负荷的替代标志物。

主要发现

  • 治疗前血浆ctHPV DNA在局部晚期宫颈癌中检出率为94.4%,在早期宫颈癌中为26.7%,癌前病变患者所有样本均为阴性。
  • 较高的ctHPV DNA水平与较高的FIGO2018分期相关。
  • 局部晚期宫颈癌患者中,治疗结束时持续检出ctHPV DNA者无进展生存期显著差于清除ctHPV DNA者(P=0.007)。
  • 治疗前血浆总ctDNA水平高于中位数的患者无进展生存期差于低于中位数的患者(P=0.026)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tumor cells release fragments of their DNA into the circulation, so called cell-free tumor DNA (ctDNA) or liquid biopsy. Here, we analyze if cell-free human papillomavirus DNA (ctHPV DNA) is detectable before, during and after treatment, in patients with cervical cancer or pre-malignant lesions that may develop into cervical cancer, and whether ctHPV DNA levels were correlated to patient or tumor characteristics and outcome. Furthermore, total cell-free DNA load is studied using cfAlbumin DNA as a surrogate marker. METHODS: 18 patients with locally advanced CC (LACC), 15 patients with early stage CC (ESCC) and 21 patients with pre-malignant lesions, all with verified HPV16, 18 or 45-positive lesions, were included. Pre- during- and post-treatment plasma were tested for HPV16, 18 & 45 and total cfDNA load using droplet digital PCR. RESULTS: ctHPV DNA was found in 94.4% and 26.7% of pre-treatment plasma of patients with LACC and ESCC respectively, while all samples from patients with pre-malignant lesions were negative. Higher levels of ctHPV DNA were correlated to higher FIGO2018 stage. Patients with LACC and persistent ctHPV DNA at end-of-treatment had significantly worse progression-free survival (PFS) than patients who had cleared the ctHPV DNA (p = 0.007). Patients with total ctDNA-levels above median in pre-treatment plasma had a worse PFS (p = 0.026), compared to patients with total ctDNA-levels below median. CONCLUSION: ctHPV DNA is a promising prognostic biomarker in locally advanced cervical cancer that should be studied further for clinical use.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sivars L, Hellman K, Crona Guterstam Y, et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer. Gynecol Oncol. 2022. PMID: 35918201. doi:10.1016/j.ygyno.2022.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。